Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$65.87 USD

65.87
249,201

+0.44 (0.67%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $66.51 +0.64 (0.97%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Zacks Equity Research

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.

Zacks Equity Research

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

by Zacks Equity Research

Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.

Zacks Equity Research

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

Zacks Equity Research

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Zacks Equity Research

Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.

Zacks Equity Research

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Zacks Equity Research

Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.

Zacks Equity Research

What Will Sitio Royalties' (STR) Q1 Earnings Unveil?

by Zacks Equity Research

Sitio Royalties (STR) beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, resulting in an earnings surprise of 155.6%, on average.

Zacks Equity Research

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.

Zacks Equity Research

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.

Zacks Equity Research

Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.

Zacks Equity Research

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.

Zacks Equity Research

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Zacks Equity Research

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

by Zacks Equity Research

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Zacks Equity Research

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Zacks Equity Research

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks Equity Research

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

by Zacks Equity Research

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Zacks Equity Research

United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Zacks Equity Research

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Zacks Equity Research

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.